Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07324616 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
A Phase 1 study of Hepatic Impairment (HI), sponsored by Edgewise Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT07324616: Recruiting Phase 1 study of Hepatic Impairment (HI), sponsored by Edgewise Therapeutics.
NCT07324616 is a Phase 1 study of Hepatic Impairment (HI) that is actively recruiting participants, run by Edgewise Therapeutics. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07324616, a Phase 1 study of Hepatic Impairment (HI), is actively recruiting participants, sponsored by Edgewise Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.
Conditions Studied
Interventions
- DRUG EDG-7500
Study Locations (2)
Florida
- The University of Miami Division of Clinical Pharmacology - Miami
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-01-26 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What NCT07324616 shows while recruiting
NCT07324616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Hepatic Impairment (HI) appearing as the primary indexed condition, and to 1 intervention - of which EDG-7500 is the first listed.
NCT07324616 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07324616 about?
NCT07324616 is a clinical study titled "A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment". The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels...
What is the current status of trial NCT07324616?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-01-26. Estimated completion is 2026-05.
What conditions does trial NCT07324616 study?
This clinical trial studies the following conditions: Hepatic Impairment (HI).
What interventions are being tested in trial NCT07324616?
The interventions under investigation include: EDG-7500 (DRUG).
Who is sponsoring clinical trial NCT07324616?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07324616 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment (HI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07324616's enrollment target sits among peer trials
32 1297th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI